Nightingale Health Plc, a leader in disease risk detection and preventative health, has received further regulatory approval from Singapore's Health Sciences Authority (HSA), the national regulator for medical devices, therapeutics, and healthcare products.
Earlier this year, Nightingale Health announced its first approval, which covered the analysis of eight common clinical biomarkers, including total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, apolipoprotein A1, apolipoprotein B, glucose, and creatinine. The recent approval expands this to include the analysis of various fatty acids: total fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, saturated fatty acids, omega-3 fatty acids, and omega-6 fatty acids.
Earlier this year, Nightingale Health announced its first approval, which covered the analysis of eight common clinical biomarkers, including total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, apolipoprotein A1, apolipoprotein B, glucose, and creatinine. The recent approval expands this to include the analysis of various fatty acids: total fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, saturated fatty acids, omega-3 fatty acids, and omega-6 fatty acids.
About this article
From the Medical Directory library. For advice about your own health, speak to your healthcare professional.
JOIN THE CONVERSATION
No comments yet. Add a thoughtful question or comment about this article.